Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $104.37 USD
Change Today -4.17 / -3.84%
Volume 1.4M
As of 8:10 PM 07/27/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Richard S. Levy M.D.

Chief Drug Development Officer and Executive Vice President, Incyte Corporation
AgeTotal Calculated CompensationThis person is connected to 5 board members in 1 different organizations across 2 different industries.

See Board Relationships
57$2,001,918
As of Fiscal Year 2014

Background*

Dr. Richard S. Levy, also known as Rich, M.D. has been the Chief Drug Development Officer & Medical Officer and Executive Vice President of Incyte Corporation since January 2009. Dr. Levy served as the Senior Vice President of Drug Development of Incyte Corporation since August 26, 2003. He has over 12 years of experience in the pharmaceutical and biotechnology sectors through his prior positions at Celgene, DuPont Pharmaceuticals and Novartis. Most recently, he served ...

Read Full Background

Corporate Headquarters*

1801 Augustine Cut-Off
Wilmington, Delaware 19803

United States

Phone: 302-498-6700
Fax: --

Board Members Memberships*

2014-Present
Non-Executive Director

Education*

MD
The University of Pennsylvania
BA
Brown University

Other Affiliations*

Annual Compensation*

Salary$402,977
Total Annual Compensation$402,977

Stock Options*

Restricted Stock Awards$324,945
All Other Compensation$6,818
Exercised Options317,000
Exercised Options Value$17,080,779
Exercisable Options216,888
Exercisable Options Value$12,035,621
Unexercisable Options96,977
Unexercisable Options Value$3,656,803
Total Value of Options$32,773,203
Total Number of Options630,865

Total Compensation*

Total Annual Cash Compensation$701,975
Total Short Term Compensation$402,977
Other Long Term Compensation$331,763
Total Calculated Compensation$2,001,918
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INCY:US $104.37 USD -4.17

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Richard F. Pops Chairman of the Board and Chief Executive Officer
Alkermes plc
$854.7K
Harvey J. Berger M.D.Principal Founder, Chairman, Chief Executive Officer and President
Ariad Pharmaceuticals Inc.
$1.4M
Jean-Jacques Bienaime MBAChairman and Chief Executive Officer
BioMarin Pharmaceutical Inc.
$916.0K
Jeffrey M. Leiden M.D., Ph.D.Chairman, Chief Executive Officer and President
Vertex Pharmaceuticals Incorporated
$1.1M
Bruce C. Cozadd Co-Founder, Executive Chairman and Chief Executive Officer
Jazz Pharmaceuticals Public Limited Company
$830.0K
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INCYTE CORP, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.